<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965259</url>
  </required_header>
  <id_info>
    <org_study_id>AHCC10 ELEGANCE</org_study_id>
    <nct_id>NCT04965259</nct_id>
  </id_info>
  <brief_title>Early Detection of Hepatocellular Carcinoma in a High-risk Prospective Cohort (ELEGANCE)</brief_title>
  <official_title>Early Detection of Hepatocellular Carcinoma (HCC): miRNA, Microbiome and Imaging Biomarkers in the Evolution of Chronic Liver Disease in a High-risk Prospective Cohort (ELEGANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Singapore Phenome Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang Technological University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MiRXES Pte Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Perspectum Asia Pte Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asian Microbiome Library Pte Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is the 2nd most common cause of cancer death globally but only&#xD;
      20% are diagnosed in its early stages where cure is possible. Current standard-of-care&#xD;
      surveillance of patients at high risk of developing HCC with 6-monthly serum&#xD;
      alpha-fetoprotein (AFP) and ultrasound imaging (US) has a sensitivity of approximately 63%&#xD;
      for detecting early HCC. There is an urgent need for a more efficacious and convenient&#xD;
      modality of surveillance of high-risk patients to diagnose HCC at an early stage.&#xD;
&#xD;
      This prospective study aims to address this unmet clinical need by validating a panel of&#xD;
      circulating miRNA biomarkers for the detection of early HCC in a cohort of high-risk&#xD;
      patients.&#xD;
&#xD;
      Additionally, this study also aims to develop a multi-parametric MRI-based AI algorithm to&#xD;
      quantify individual risks of developing HCC and to predict the progression of chronic liver&#xD;
      disease in this cohort to enable targeted surveillance. Lastly, by identifying changes in the&#xD;
      microbiome and metabolites as HCC develops in this cohort enables the establishment of&#xD;
      actionable biomarkers that can prevent and predict the development of HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will receive 6-monthly standard-of-care surveillance (US, serum AFP and&#xD;
      liver function test) for HCC until end of study or up to a maximum of 7 assessments (1&#xD;
      baseline and 6 follow-up assessments). Patients with elevated AFP or abnormalities detected&#xD;
      on US will be investigated with multi-phasic CT scan or MRI to confirm or refute the&#xD;
      diagnosis of HCC. Additionally, patients shall be scheduled for sequential bio-samples&#xD;
      collection (blood, urine and stool) and blood tests (Hba1c and Lipid Panel) during the course&#xD;
      of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">February 21, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the profile of circulating micro-RNA biomarkers as high-risk patients develop HCC</measure>
    <time_frame>Baseline and every 6 months thereafter, and at HCC diagnosis every 6 months thereafter up to 12 months</time_frame>
    <description>Changes in the profile of circulating micro-RNA biomarkers as high-risk patients develop HCC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>value of cT1, PDFF and T2* levels to predict individual's risk of developing and progression of HCC.</measure>
    <time_frame>Baseline and upon elevated AFP or US which is suggestive of HCC, up to 4 years.</time_frame>
    <description>value of cT1, PDFF and T2* levels to predict individual's risk of developing and progression of HCC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the profile of gut microbiota as high-risk patients develop HCC.</measure>
    <time_frame>Baseline and every 6 months thereafter, up to 48 months</time_frame>
    <description>Changes in the profile of gut microbiota as high-risk patients develop HCC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the profile of metabolome in urine and plasma as high-risk patients develop HCC.</measure>
    <time_frame>Baseline and every 6 months thereafter, up to 48 months.</time_frame>
    <description>Changes in the profile of metabolome in urine and plasma as high-risk patients develop HCC.</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Liver Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bloods shall be used for relevant laboratory assessments. Blood, urine and stool samples&#xD;
      shall be used for miRNA, microbiome and metabolome profiling.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at high-risk of developing HCC forming a cohort of 1,200 patients with cirrhosis&#xD;
        from any etiology, 500 chronic hepatitis B without significant cirrhosis, 100 chronic&#xD;
        hepatitis C without significant cirrhosis and 200 NAFLD/NASH without significant cirrhosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients, 50 to 90 years of ago at the time of signing the informed&#xD;
             consent form.&#xD;
&#xD;
          -  Patient has serum alpha-fetoprotein (AFP) within normal range of the investigating&#xD;
             laboratory in the past 3 months&#xD;
&#xD;
          -  Patient has ultrasound hepatobiliary system (US HBS) that does not show lesion&#xD;
             suspicious for HCC or, CT / MRI scan that exclude HCC, in the past 3 months&#xD;
&#xD;
          -  Patient has chronic liver disease other than HCC in the last 5 years&#xD;
&#xD;
          -  Patient is estimated to survive more than 3 years&#xD;
&#xD;
          -  Patient with any of the following chronic liver disease:&#xD;
&#xD;
               1. liver cirrhosis of any etiology, identified by elastography (liver stiffness &gt; 13&#xD;
                  kPa), US, CT, MRI or liver biopsy, Child-Pugh class A and B (based on the&#xD;
                  judgement of the Investigator)&#xD;
&#xD;
               2. non-cirrhotic chronic viral hepatitis (B or C) or both&#xD;
&#xD;
               3. non-alcoholic fatty liver disease (NAFLD)&#xD;
&#xD;
               4. non-alcoholic steatohepatitis (NASH)&#xD;
&#xD;
          -  Patient is able to comply with scheduled visits, assessments and other study&#xD;
             procedures&#xD;
&#xD;
          -  Patient is willing to provide informed consent before enrolment in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with confirmed diagnosis of HCC by the American Association for the Study of&#xD;
             the Liver Disease (AASLDC) imaging criteria or histology / cytology within the last 5&#xD;
             years&#xD;
&#xD;
          -  Patient with Child-Pugh C cirrhosis at time of enrolment (based on the judgement of&#xD;
             the Investigator)&#xD;
&#xD;
          -  Patient with active hepatic encephalopathy at time of enrolment&#xD;
&#xD;
          -  Patient has psychiatric or addictive disorders that may compromise his/her ability to&#xD;
             give informed consent, or to comply with the study procedures&#xD;
&#xD;
          -  Patient is unable to provide informed consent or refuse blood taking&#xD;
&#xD;
          -  Patient has any other condition which, in the opinion of the Investigators, would make&#xD;
             the patient unsuitable for enrolment or could interfere with completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierce Chow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierce Chow, MD, PhD</last_name>
    <phone>+65 6436 8000</phone>
    <email>pierce.chow.k.h@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guan Huei LEE, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Bukit Merah</name>
      <address>
        <city>Singapore</city>
        <zip>150163</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina WEE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Outram</name>
      <address>
        <city>Singapore</city>
        <zip>168937</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kok Kiong ONG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Pik Eu CHANG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169690</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierce CHOW, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Han Chong TOH, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Lyn YANG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Marine Parade</name>
      <address>
        <city>Singapore</city>
        <zip>440080</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kee Tung TAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Bedok</name>
      <address>
        <city>Singapore</city>
        <zip>469662</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oi Fong CHONG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Pasir Ris</name>
      <address>
        <city>Singapore</city>
        <zip>519457</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ngiap Chuan TAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Tampines</name>
      <address>
        <city>Singapore</city>
        <zip>529203</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SULAIHA Binte Ithnin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Yu Jun WONG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sengkang General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>544886</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris San Choon KONG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Sengkang</name>
      <address>
        <city>Singapore</city>
        <zip>545025</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Jun CHOO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SingHealth Polyclinics - Punggol</name>
      <address>
        <city>Singapore</city>
        <zip>820681</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Yi YEAP, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma(HCC)</keyword>
  <keyword>Surveillance</keyword>
  <keyword>Patients-at-risk</keyword>
  <keyword>miRNA</keyword>
  <keyword>Precision medicine</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Metabolites</keyword>
  <keyword>Microbiome biomarkers</keyword>
  <keyword>Circulating biomarkers</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

